Why is Hemab Therapeutics stock sliding today?
Hemab Therapeutics (HMAB) shares fell 5.3% premarket after reporting a wider Q3 2026 net loss of $27.3M ($0.58/share), up from $17.1M YoY, due to higher R&D and admin costs. CEO Benny Sørensen noted pipeline progress, including a Phase 3 study start. Cash reserves were $430.2M. LifeSci Capital initiated coverage with an Outperform rating and $65 target. Broader market declines also pressured the stock.
How this was made
The 30-second read
Why it matters
The earnings miss highlights escalating operating costs and a widening loss, pressuring the stock in pre‑market trading.
Market read
The earnings release caused a 5.3% pre‑market decline, reflecting immediate market reaction to the widened loss and higher expenses.
What to watch
LifeSci Capital's $65 price target suggests some analysts see upside potential despite the loss.
Background
Hemab Therapeutics is a newly public clinical‑stage biotech that completed its IPO in May 2026.
Market effects
Biotech sector may see broader risk‑off pressure as investors reassess cash burn in clinical‑stage companies.
US biotech stocks could face heightened volatility in early trading.
Limited to US markets; no immediate global macro effect.
Counterpoint
The company still holds $430M cash runway to 2029, which could support a rebound if upcoming trial data are positive.
Key entities
- companyHemab Therapeutics Holdings
Clinical‑stage biotech reporting Q3 2026 results.
- analystLifeSci Capital
Initiated coverage with an Outperform rating and $65 price target.



